Other MA plans are downsizing, upset about coding changes and lobbying for higher rates. Alignment is growing and unbothered by the policy and payment fuss. CEO John Kao lays out how his company is breaking away from the pack.
Alignment Healthcare’s idiosyncratic take on Medicare Advantage Read More »
The acquisition, announced Tuesday, would expand Sutter outside its home state of California and into the Midwest. The nonprofits expect the deal to close by the end of the year.
Sutter, Allina Health to form $26B nonprofit system Read More »
En Chile, el formato móvil tiene una gran demanda. Aquí se están desarrollando activamente las redes móviles, los usuarios están acostumbrados a resolver sus tareas cotidianas a través del teléfono y el deporte ocupa un lugar importante en la vida. El …
Bet365 APP: cómo apostar en deportes desde el móvil Read More »
Turco, an interventional cardiologist, has held roles including CEO of JC Medical and chief medical officer of Medtronic’s aortic and peripheral vascular business.
PFA startup Field Medical appoints Mark Turco as CEO Read More »
Protagonist Therapeutics will now sit back and collect cash from the J&J partnership, including an immediate $50 million payment.
Protagonist’s First Approval Spells Trouble for Pharma’s Immunology Heavyweights Read More »
Grade is leaving after a two-year stint defined by changes to Baxter’s business, including the sale of its kidney care unit.
Nearly all physicians said they had already used AI in their practice or are interested in doing so, according to the survey by Doximity. But more than 70% said accuracy and reliability were a top barrier to adoption.
Physicians still concerned about AI accuracy amid rapid adoption: survey Read More »
Heath Secretary Robert F. Kennedy Jr.’s efforts to overhaul vaccine policy are likely illegal, a Massachusetts District Court Judge ruled; Structure’s GLP-1 weight loss pill succeeds in Phase 2 while Rhythm’s Phase 3 basket trial fails to find the beat; Eli Lilly warns of potential safety risks of taking compounded tirzepatide, and Novo Nordisk is
Icotyde is backed by data from the Phase 3 ICONIC program which, among other advantages, showed significant superiority over Bristol Myers Squibb’s Sotyktu.
J&J Wins FDA Nod for First Targeted Oral Anti-IL-23 Therapy for Plaque Psoriasis Read More »
La Pseudomonas aeruginosa es considerada uno de los patógenos más preocupantes a nivel global debido a su capacidad para adaptarse y desarrollar resistencia a la mayoría de los antibióticos disponibles, lo que provoca miles de muertes anuales en pacientes vulnerables. Su …
